GLOBAL MYASTHENIA GRAVIS DRUGS MARKET 2018 BY MANUFACTURERS, REGIONS, TYPE AND APPLICATION, FORECAST TO 2023

Jan 2019 147

Delivery of the Report will take 2-3 working days once order is placed.

Synopsis

Acetylcholine esterase (AChE) inhibitors are considered to be the basic treatment of myasthenia gravis (MG). Edrophonium is primarily used as a diagnostic tool owing to its short half-life. Pyridostigmine is used for long-term maintenance.

Scope of the Report:
This report focuses on the Myasthenia Gravis Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The market is witnessing the rapid development of novel drugs such as monoclonal antibodies, which is one of the primary factors driving this market’s growth prospects. Most drug manufacturers are increasingly focussing on the development of monoclonal antibodies, as they act specifically on target cells; thereby, leading to lower side effects. Since conventional therapies such as acetylcholinesterase inhibitor, oral steroids, and immunomodulatory agents are associated with more side effects, physicians prefer to prescribe high efficacious monoclonal antibodies.
The worldwide market for Myasthenia Gravis Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers
- Flamel Technologies
- Roche
- Grifols
- Pfizer
- Shire
- Novartis
- Valeant
- Alexion
- Catalyst
- CSL
- Curavac
- Cytokinetics
- Galencia
- GlaxoSmithKline
- Lupin Pharmaceuticals
- Mitsubishi Tanabe Pharma

Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
- Anticholinesterases
- Immunosuppressants
- Intravenous Immune Globulins

Market Segment by Applications, can be divided into
- Hospitals
- Clinics

There are 15 Chapters to deeply display the global Myasthenia Gravis Drugs market.
Chapter 1, to describe Myasthenia Gravis Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Myasthenia Gravis Drugs, with sales, revenue, and price of Myasthenia Gravis Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Myasthenia Gravis Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Myasthenia Gravis Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Myasthenia Gravis Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Table of Contents

Related reports :

(Jan 19)

Apigenin is a polyphenol, and is one of the flavonoids found in many of the foods consumed by humans. Scope of the Report:...

(Jan 19)

Aplastic anaemia is a rare disease in which the bone marrow and the hematopoietic stem cells that reside there are damaged. S...

(Jan 19)

Aplastic anaemia is a rare disease in which the bone marrow and the hematopoietic stem cells that reside there are damaged. S...

(Jan 19)

Aplastic anaemia is a rare disease in which the bone marrow and the hematopoietic stem cells that reside there are damaged. S...

(Jan 19)

Eltrombopag (rINN, codenamed SB-497115-GR) is a medication that has been developed for certain conditions that lead to thrombocytopenia (abn...

(Jan 19)

Eltrombopag (rINN, codenamed SB-497115-GR) is a medication that has been developed for certain conditions that lead to thrombocytopenia (abn...

GLOBAL MYASTHENIA GRAVIS DRUGS MARKET 2018 BY MANUFACTURERS, REGIONS, TYPE AND APPLICATION, FORECAST TO 2023


Share this report on:

Subscription Option


Using our subscription option, you get access to Market Research Reports and industry data of Medicine and Pharmacy market as per your needs. Get the best of Medicine and Pharmacy research reports by utilizing your research budgets in an optimum way. Contact for details

Contact for reports

*

We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy